New Developments in Treating Genetic Disorders: The Global Market

Report Code: BIO056B

Publish Date: Mar 2010

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The global market for products to treat genetic disorders was worth $12.8 billion in 2009 and is estimated to reach $17.3 billion by 2014, a compound annual growth rate (CAGR) of more than 6%.
  • The gene mutation disorder segment is the largest in terms of sales and is considered to be a more successful area for development activity. This segment generated $11.3 billion in 2009 and is projected to increase at a compound annual growth rate (CAGR) of 6.5% to reach $15.6 billion in 2014.
  • The chromosomal disorders segment was valued at $1.5 billion in 2009. By 2014, this market is expected to be worth $1.8 billion, a compound annual growth rate (CAGR) of 3.7%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES 

The goal of the study, New Developments in Treating Genetic Disorders: The Global Market, is to provide an overview of a range of genetic disorders, both mutation and chromosomal in nature, and provide market summaries and new research and developments. The market is discussed for the 2009 year and forecasts are provided through 2014. Product descriptions, discussions of new research, and company profiles are also provided. 
The study also covers issues affecting the current and forecasted market, patent information, and a list of key organizations covering genetic disorders.
REASONS FOR DOING THE STUDY
 
Treating genetic disorders has become one of the most complicated areas of medicine and there are several thousand disorders resulting from gene mutations and chromosomal malfunctions. Scientists have studied these disorders for decades; however, there remain only a limited number of disorders with available treatments. The demand for new development is strong with biopharmaceutical companies, governments, private organizations, and universities actively seeking new treatments. Several new developments have emerged over the past few years resulting in markets worth billions of dollars. This study will explore research and development in several select areas of genetic disorders and discuss the current and potential market growth.
SCOPE OF REPORT
 
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for a number of genetic disorders, including prevalence and incidence; biopharmaceutical treatments; and research and development activities. The geographic scope of this study is worldwide. The report covers a range of genetic disorders, specifically including: 
  • Cystic fibrosis
  • Fabry disease
  • Gaucher’s disease
  • Hemophilia
  • Huntington’s disease
  • Hunter syndrome
  • Hurler syndrome
  • Klinefelter syndrome
  • Maroteaux–Lamy syndrome
  • Phenylketonuria (PKU)
  • Prader–Willi syndrome
  • Pompe disease
  • Turner’s syndrome

Each market segment discussion provides detailed information based on current product availability, uses of products, forecasts, and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

METHODOLOGY 
The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, research specialists, government departments, and other key representatives involved in the genetic disorder industry. Secondary methods included published literature, investment reports, company literature, and various business journals that cover genetic diseases and their products, new technologies and related information. 
Market data for this report pertains to the worldwide market. All information is displayed using U.S. dollars at the manufacturers’ level. The base year of the report is 2009, with historical data provided for 2007 and 2008, and forecast data provided through 2014. Historical, base year, and forecast data are provided for each market segment of the report. Compound annual growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and other trends. Competitor market share estimates are provided for each market segment for the 2009 base year with a forecast through 2014.
ANALYST CREDENTIALS
 
Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over–the–counter pharmaceuticals, medical devices, animal health products, and emerging healthcare technologies. Ms. Elder has more than 13 years of experience in the healthcare industry, specializing in market research for the past 10 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets. 
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: New Developments in Treating Genetic Disorders: The Global Market169Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY3Free
Chapter- 3: INDUSTRY OVERVIEW20Free
Chapter- 4: ISSUES AFFECTING THE MARKET6Free
Chapter- 5: GENE MUTATION DISORDERS53Free
Chapter- 6: CHROMOSONAL DISORDERS16Free
Chapter- 7: MARKET SUMMARY9Free
Chapter- 8: TECHNOLOGY12Free
Chapter- 9: C. CRAMER & CO. GMBH24Free
Chapter- 10: APPENDIX23Free
Published - Apr-2006| Analyst - Amy Brock| Code - BIO056A

Report Highlights

  • The U.S. market for therapeutics and diagnostics for genetic diseases reached $4.8 billion in 2005 and is expected to grow at an average annual rate of 8.7%, reaching $7.3 billion by 2010.
  • Transfusions and dialysis comprised 44% of the total market in 2005 and are projected to grow at an annual rate of 8.0%.
  • Pharmaceuticals for genetic disease treatment reached $2.7 billion in 2005. They are expected to grow at an average annual rate of 9.4% to reach a projected $2.7 billion by 2010.
  • The market for diagnostic testing reached $663.6 million in 2005. It is projected to grow at an annual rate of 9.3% to reach a projected $1036.7 million in 2010.
  • The market for transplants to treat genetic diseases was $280.6 million in 2005 and is expected to grow at an average annual rate of 8.2% to reach a projected $416.1 million in 2010.

Related Reports

Recent Reports

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Induced Pluripotent Stem Cells: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO135F

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.

Commercial Amino Acids

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO007N

The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
New Developments in Treating Genetic Disorders: The Global Market
Customize Report